Exicure, Inc. XCUR

XCUR Company Overview

Exicure, Inc. (Nasdaq: XCUR) is a U.S.-based biotechnology company that historically focused on developing nucleic acid-based therapeutics utilizing spherical nucleic acid (SNA) technology for immuno-oncology, neurology, inflammatory disorders, and genetic diseases. The company operated within the biotechnology and pharmaceutical research industries, with its core value proposition centered on the delivery and cellular uptake advantages associated with SNA constructs. Exicure’s earlier pipeline included therapeutic candidates targeting conditions such as scalp psoriasis and neurodegenerative diseases, though several clinical and preclinical programs were discontinued or deprioritized as the company restructured operations.

The company was founded in 2011 and emerged from research associated with Northwestern University and nanotechnology scientist Chad Mirkin. Over time, Exicure evolved from a research-driven nanomedicine developer into a company pursuing strategic alternatives and capital restructuring following operational setbacks, financing challenges, and program discontinuations. Public disclosures in recent years indicated reductions in research activity and workforce restructuring while management evaluated financing, partnership, and acquisition opportunities. Data regarding long-term operational direction remains limited in some areas based on available public sources.